Issues‎ > ‎Vol4n1‎ > ‎

jsmc-10050


A POTENTIAL FOR THE SHORTEST TREATMENT OF MODERATELY SEVERE ACNE VULGARIS WITH THE USE OF MINIMUM- AND LOW- DOSE OF ISOTRETINOIN


Faraedon Kaftan *


* Department of Medicine, School of Medicine, Faculty of Medical Sciences, University of Sulaimani.


Submitted: 22/7/2013; Accepted: 7/11/2013Published 1/6/2014


ABSTRACT


Background

Acne vulgaris is a common human skin disease. Isotretinoin is one of many pharmaceutical agents used in the treatment of patients with moderate and severe forms of acne.

Objectives

To use minimum- and low-dose of isotretinoin for the shortest period in the treatment of patients with moderate acne vulgaris.

Patients and Methods

We have carried out this study on 210 patients with moderate papulopustular acne. From the beginning to compare between the patients they were divided into two age groups: the first group between 12 and 20 years; the second group between 21 and 35 years. Both groups of patients were followed up for four years. All patients were treated for 4 months with isotroin capsules with a dosage of 40 mg/day in two divided doses for two months and then decreased to 20 mg/day for another two months. Before and after the two and four months treatment laboratory tests were carried out for complete blood cell counts, liver and lipid profiles (cholesterol and triglycerides). Pregnancy tests were also carried out before treatment in female patients of child-bearing potential and interested in this regimen.

Results

The first group included 110 patients, with a female/male ratio of 2:1, mean age 17.2 years, and a mean body weight of 56.3 kg. 99.1% of the patients achieved complete remission, whilst 0.9% of the patients failed to respond to the treatment. The relapse rate was 3.6% and the mean total dosage of isotroin was 63.9 mg/kg, whereas and the daily dose of the drug was 0.5 mg/kg/day. The second group included 100 patients, with a female/male ratio of 2.6:1, mean age 25.3 years, and a mean body weight of 66.8 kg. 99% of the patients achieved complete remission, whilst 1% of the patients failed to respond to the treatment. The relapse rate was 4%, the mean total dosage of isotroin was 53.9 mg/kg and the daily dose of the drug was 0.45 mg/kg/day. In both groups, the most common side effects in all the patients were mild to severe cheilitis and dryness of the skin. Only one patient suffered of epistaxis. After the 4-month treatment only one of the patients had high serum triglycerides. None of the patient had elevation of liver enzymes.

Conclusion

In moderately severe acne vulgaris, excellent results can be obtained with minimum- and low-dose oral isotretinoin for only four months of treatment.

KEYWORDS

Isotretinoin, Moderate acne vulgaris.

References 

1- Adityan B, Kumari R, Thappa DM (2009). Scoring systems in acne vulgaris. Indian J Dermatol Venereol Leprol 75 (3): 323–6. 

2- Nobukazu HAYASHI, Hirohiko AKAMATSU, Makoto KAWASHIMA (2008). Establishment of grading criteria for acne severity. Journal of Dermatology; 35: 255–260

3- Batra RS (2007). Acne. In: Kenneth AA, Hsu JTS, (editors). Manual of Dermatologic Therapeutics. Philadelphia: Lippincott Williams & Wilkins, pp. 3-17.

4- Faraedon Mohamad Aziz Kaftan (2005). The frequency of skin diseases among infants and children in Sulaimani City. A thesis submitted to the College of Medicine, University of Sulaimani-Iraq as a partial fulfillment of the requirements for the degree of M. Sc. in Dermatology and Venereology.  

5- Wysowski DK, Swann J, Vega A (2002). Use of isotretinoin (Accutane) in the United States: rapid increase from 1992 through 2000. J Am Acad Dermatol 46: 505–9.

6- Klasco RK (editor) (2006). Drugdex system, vol. 128. Greenwood Village (CO): Thomson Micromedex.

7- Strauss J, Krowchuk D, Leyden J, Lucky A, Shalita A, Siegfried E, et al et al (2007). Guidelines of care for acne vulgaris management. J Am Acad Dermatol 56 (4): 651–63.  

8- Amichai B, Grunwald MH (2000). Isotretinoin in dermatology. J Dermatol Treat 11:219-40.

9- Amichai B, Shemer A, Grunwald MH (2006). Low-dose isotretinoin in the treatment of acne vulgaris.  J Am Acad Dermatol 54:644-6.

10- Kligman AM (1996). Treating severe inflammatory acne: the last word. Cutis 57:26-7.

11- Di Giovanna JJ (2001). Systemic retinoid therapy. Dermatol Clin 19:161-7. 

12- Del Rosso JQ (2007). Recently approved systemic therapies for acne vulgaris and rosacea. Cutis 80:113-20.

13- Zouboulis CC (2006). The truth behind this undeniable efficacy–recurrence rates and relapse risk factors of acne treatment with oral isotretinoin. Dermatology 212(2): 99–100.  

14- Dhir R, Gehi NP, Agarwal R, More YE (2008). Oral isotretinoin is as effective as a combination of oral isotretinoin and topical anti-acne agents in nodulocystic acne. Indian J Dermatol Venereol Leprol 74:187.

15- Kremer I, Gaton D, David M, Gaton E, Shapiro A (1994). Toxic effects of systemic retinoids on Meibomian glands. Ophthalmic Res 26 (2): 124–8. 

16- Griffin JN, Pinali D, Olds K, Lu N, Appleby L, Doan L, Lane MA (2010). "13-Cis-retinoic acid decreases hypothalamic cell number in vitro". Neurosci Res 68 (3): 185–90. 

17- Sakai Y, Crandall JE, Brodsky J, McCaffery P (2004). "13-cis Retinoic acid (accutane) suppresses hippocampal cell survival in mice". Ann N Y Acad Sci 1021: 436–40.  

18- Nelson AM, Cong Z, Gilliland KL, Thiboutot DM (2011). TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells. Br J Dermatol 165 (3): 526–33. 

19- Voreacos D (2007). Roche Found Liable in First Of 400 Suits Over Accutane. The Washington Post. Bloomberg News. 

20- Scheinfeld N, Bangalore S (2006). Facial edema induced by isotretinoin use: A case and a review of the side effects of isotretinoin. J Drugs Dermatol 5(5): 467–8. 

21- Milchell AA, Van Bennekom CM, Louik C (1995). A pregnancy prevention programme in women of child bearing age receiving isotretinoin. N Eng J Med 333:101-6.

22- Patton TJ, Zirwas MJ, Wolverton SE (2007). Systemic retinoids. In: Wolverton SE, (editor). Comprehensive dermatologic drug therapy. Philadelphia: Saunders, pp. 276-95.

23- Sardana K, Garg VK, Sehgal VN, Mahajan S, Bhushan P (2009). Efficacy of fixed low-dose isotretinoin (20 mg, alternate days) with topical clindamycin gel in moderately severe acne vulgaris. J Eur Acad Dermatol Venereol 23:556-60.

24- Mandekou-Lefaki I, Delli F, Teknetzis A, Euthimiadou R, Karakatsanis G (2003). Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharm Res 23:41-6.